PROCEPT BioRobotics (NASDAQ:PRCT) Stock Price Up 6.6% - Time to Buy?

PROCEPT BioRobotics logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • PROCEPT BioRobotics shares rose 6.6% to $25.35, though trading volume was 64% below its average.
  • Analysts have a consensus Hold rating and an average price target of $25.25; views range from Sell to Strong Buy.
  • Quarterly results fell short of estimates, with a $0.46-per-share loss and $98.29 million in revenue versus forecasts of a $0.39 loss and $100.52 million. Revenue still grew 18% year over year.
  • Five stocks to consider instead of PROCEPT BioRobotics.

PROCEPT BioRobotics Corporation (NASDAQ:PRCT - Get Free Report) shares rose 6.6% during trading on Wednesday. The stock traded as high as $25.18 and last traded at $25.35. 540,140 shares changed hands during trading, a decline of 64% from the average session volume of 1,503,075 shares. The stock had previously closed at $23.78.

Wall Street Analysts Forecast Growth

PRCT has been the subject of several recent analyst reports. Wells Fargo & Company cut PROCEPT BioRobotics from an "overweight" rating to an "equal weight" rating and set a $19.00 target price for the company. in a research note on Wednesday, August 5th. Truist Financial lifted their price target on PROCEPT BioRobotics from $21.00 to $24.00 and gave the company a "hold" rating in a research note on Friday, November 6th. Barclays began coverage on PROCEPT BioRobotics in a report on Tuesday, October 6th. They set an "overweight" rating and a $30.00 price target for the company. Leerink Partners upped their price objective on PROCEPT BioRobotics from $20.00 to $22.00 and gave the stock a "market perform" rating in a research report on Thursday, November 5th. Finally, Weiss Ratings restated a "sell (e+)" rating on shares of PROCEPT BioRobotics in a research report on Thursday, October 15th. Three investment analysts have rated the stock with a Strong Buy rating, two have assigned a Buy rating, nine have issued a Hold rating and two have given a Sell rating to the company's stock. Based on data from MarketBeat, the company presently has a consensus rating of "Hold" and a consensus target price of $25.25.

View Our Latest Research Report on PRCT

PROCEPT BioRobotics Stock Up 8.2%

The firm's fifty day moving average is $19.58 and its 200-day moving average is $22.89. The company has a market capitalization of $1.48 billion, a P/E ratio of -12.74 and a beta of 0.88. The company has a debt-to-equity ratio of 0.16, a quick ratio of 4.73 and a current ratio of 5.89.

PROCEPT BioRobotics (NASDAQ:PRCT - Get Free Report) last issued its quarterly earnings data on Wednesday, November 4th. The company reported ($0.46) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.07). PROCEPT BioRobotics had a negative net margin of 32.60% and a negative return on equity of 33.23%. The company had revenue of $98.29 million during the quarter, compared to the consensus estimate of $100.52 million. During the same period in the previous year, the company earned ($0.38) EPS. PROCEPT BioRobotics's revenue for the quarter was up 18.0% on a year-over-year basis. As a group, equities research analysts predict that PROCEPT BioRobotics Corporation will post -1.74 EPS for the current year.

Insider Buying and Selling at PROCEPT BioRobotics

In other news, insider Pooja Sharma sold 4,710 shares of the company's stock in a transaction on Friday, November 6th. The shares were sold at an average price of $19.71, for a total transaction of $92,834.10. Following the completion of the transaction, the insider directly owned 106,471 shares in the company, valued at approximately $2,098,543.41. This represents a 4.24% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 5,753 shares of company stock worth $114,685 over the last quarter. Insiders own 4.00% of the company's stock.

Institutional Investors Weigh In On PROCEPT BioRobotics

Several hedge funds have recently modified their holdings of the company. Johnson & Johnson bought a new stake in shares of PROCEPT BioRobotics during the second quarter worth about $8,082,263. Bank of America Corp DE bought a new position in PROCEPT BioRobotics in the 2nd quarter valued at approximately $11,656,000. Quantinno Capital Management LP bought a new position in PROCEPT BioRobotics in the 1st quarter valued at approximately $1,693,000. Corient Private Wealth LP bought a new position in PROCEPT BioRobotics in the 2nd quarter valued at approximately $2,448,000. Finally, The Manufacturers Life Insurance Company acquired a new stake in PROCEPT BioRobotics during the 2nd quarter worth approximately $1,203,000. Institutional investors and hedge funds own 89.46% of the company's stock.

About PROCEPT BioRobotics

(Get Free Report)

PROCEPT BioRobotics develops and commercializes surgical robotic systems for urology, with a focus on treating benign prostatic hyperplasia, or BPH, an enlargement of the prostate that can cause urinary symptoms. The company's core offering is Aquablation therapy, delivered using its AquaBeam Robotic System. The procedure combines imaging guidance with a surgeon-controlled, robotically assisted waterjet to remove prostate tissue. PROCEPT also offers its HYDROS Robotic System, a platform designed to deliver Aquablation therapy.

Read More

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in PROCEPT BioRobotics Right Now?

Before you consider PROCEPT BioRobotics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and PROCEPT BioRobotics wasn't on the list.

While PROCEPT BioRobotics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines